Results 51 to 60 of about 116,902 (309)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells

Cancer Management and Research, 2020
Linggang Zhu,1,2 Chu Zhu,1 Xuanxuan Wang,1 Hai Liu,1 Yanhong Zhu,1 Xiaonan Sun1 1Department of Radiation Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2Department of Radiation ...
Zhu L, Zhu C, Wang X, Liu H, Zhu Y, Sun X   +5 more
doaj  

PARP-1 inhibitory activity and docking score data for the most promising hits.

, 2017
a) PARP-1 inhibition was determined using HT Universal Colorimetric PARP Assay Kit (Cat #4677-096-k). *Docking score values of both possible NSC86342cis diastereomers.
Giorgio Colombo (65952), Elisabetta Moroni (38446), Massimiliano Meli (220602), Salete J. Baptista (3697615), Maria M. C. Silva (3697618), Teresa C. P. Dinis (455189), Jorge A. R. Salvador (538880)   +6 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

PARP-14 binds specific DNA sequences to promote Th2 cell gene expression. [PDF]

PLoS ONE, 2013
PARP-14, a member of the poly ADP-ribose polymerase super family, promotes T helper cell 2 (Th2) differentiation by regulating interleukin-4 (IL-4) and STAT6-dependent transcription.
Jonathan P Riley, Aishwarya Kulkarni, Purvi Mehrotra, Byunghee Koh, Narayanan B Perumal, Mark H Kaplan, Shreevrat Goenka   +6 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Mediprintic sp. z o.o.'s 3D printed forearm orthosis project stakeholder analysis.

Journal of Modern Science
Objectives: The purpose of the research was to perform a stakeholder analysis for the Research and Development project of Mediprintic sp. z o.o. in order to confirm correctly identified parties for cooperation within the 1.1.2 PARP Start-up Platforms ...
Andrzej Zakręcki, Piotr Zawada
doaj   +1 more source

PARP inhibitors as anticancer agents

, 2021
The PARP enzyme family is a heterogeneous group of enzymes that are involved in a myriad of intracellular processes from maintaining genomic integrity, modulating inflammatory responses, and regulating cellular metabolism, to name a few.
Oladapo, Emmanuel Taiwo
core  

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

PARP‐1 regulates DNA repair factor availability

EMBO Molecular Medicine, 2018
PARP‐1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP‐1 enzymatic
Matthew J Schiewer, Amy C Mandigo, Nicolas Gordon, Fangjin Huang, Sanchaika Gaur, Renée de Leeuw, Shuang G Zhao, Joseph Evans, Sumin Han, Theodore Parsons, Ruth Birbe, Peter McCue, Christopher McNair, Saswati N Chand, Ylenia Cendon‐Florez, Peter Gallagher, Jennifer J McCann, Neermala Poudel Neupane, Ayesha A Shafi, Emanuela Dylgjeri, Lucas J Brand, Tapio Visakorpi, Ganesh V Raj, Costas D Lallas, Edouard J Trabulsi, Leonard G Gomella, Adam P Dicker, Wm. Kevin Kelly, Benjamin E Leiby, Beatrice Knudsen, Felix Y Feng, Karen E Knudsen   +31 more
doaj   +1 more source